Last reviewed 2026-04-20 · How we verify

Treatment sequence 2

At a glance

Approved indications

No approved indications tracked.

Common side effects

• DIARRHOEA
• RASH
• FATIGUE
• NAUSEA
• NAIL DISORDER
• HYPERTRANSAMINASAEMIA
• ARTHRALGIA
• EPISTAXIS
• PRURITUS
• PARONYCHIA
• DRY SKIN
• VOMITING

Key clinical trials

• A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
• Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
• An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (PHASE1)
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
• Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (PHASE3)
• Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
• A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (PHASE2)
• Study in Adult Patients With Moderate to Severe Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Treatment sequence 2 CI brief — competitive landscape report
• Treatment sequence 2 updates RSS · CI watch RSS
• Janssen Research & Development, LLC portfolio CI